Geode Capital Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-315,377
| Closed | -$473K | – | 4831 |
|
|
2023
Q1 | $473K | Hold |
315,377
| – | – | ﹤0.01% | 3665 |
|
|
2022
Q4 | $314K | Sell |
315,377
-773
| -0.2% | -$1.04K | ﹤0.01% | 3870 |
|
|
2022
Q3 | $569K | Buy |
316,150
+4,686
| +2% | +$13.6K | ﹤0.01% | 3656 |
|
|
2022
Q2 | $903K | Sell |
311,464
-227,546
| -42% | -$561K | ﹤0.01% | 3475 |
|
|
2022
Q1 | $1.49M | Sell |
539,010
-82,442
| -13% | -$259K | ﹤0.01% | 3416 |
|
|
2021
Q4 | $2.9M | Buy |
621,452
+167,119
| +37% | +$1.04M | ﹤0.01% | 3188 |
|
|
2021
Q3 | $3.87M | Sell |
454,333
-37,503
| -8% | -$530K | ﹤0.01% | 3058 |
|
|
2021
Q2 | $8.07M | Buy |
491,836
+36,526
| +8% | +$738K | ﹤0.01% | 2615 |
|
|
2021
Q1 | $10.1M | Buy |
455,310
+80,912
| +22% | +$2.21M | ﹤0.01% | 2362 |
|
|
2020
Q4 | $11.6M | Buy |
374,398
+27,205
| +8% | +$688K | ﹤0.01% | 2066 |
|
|
2020
Q3 | $7.05M | Buy |
347,193
+102,685
| +42% | +$1.8M | ﹤0.01% | 2182 |
|
|
2020
Q2 | $3.75M | Buy |
244,508
+53,004
| +28% | +$611K | ﹤0.01% | 2499 |
|
|
2020
Q1 | $1.48M | Buy |
191,504
+15,785
| +9% | +$193K | ﹤0.01% | 2833 |
|
|
2019
Q4 | $2.51M | Buy |
175,719
+13,548
| +8% | +$209K | ﹤0.01% | 2873 |
|
|
2019
Q3 | $2.44M | Buy |
162,171
+121,894
| +303% | +$1.9M | ﹤0.01% | 2815 |
|
|
2019
Q2 | $576K | Buy |
+40,277
| New | +$643K | ﹤0.01% | 3414 |
|
Geode Capital Management's TCRR Position: Q2 2023 in Review
Geode Capital Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 315,377 shares — an estimated $473K sold.
Geode Capital Management first reported a position in TCRR in Q2 2019 and held it in 16 quarters. The position peaked at $11.6M in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Geode Capital Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Geode Capital Management sold 315,377 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $473K.
- Geode Capital Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- Geode Capital Management's TCR2 Therapeutics Inc. Common Stock position peaked at $11.6M in Q4 2020.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Geode Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.